CompanyGraph
At a glance
- Depends onMidstream position: 5 outgoing, 4 incoming connections
- FinancialsLow earnings quality
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
3.28BCNY489.67M · vs all stocks (USD)
Revenue (TTM)
491.90MCNY73.40M · vs all stocks (USD)
Profit Margin
-55.05%Beta
-0.3290xvs all stocks
52-Week Change
-32.66%vs all stocks
Market Capitalization
3.28BCNY489.67M · vs all stocks (USD)
Enterprise Value
2.50BCNY372.49M · vs all stocks (USD)
Price to Sales (TTM)
6.67xPrice to Book (MRQ)
1.58xEnterprise to Revenue
5.08xEnterprise to EBITDA
-27.09xGross Margin
24.15%Profit Margin
-55.05%Operating Margin
-107.67%Return on Assets (TTM)
-4.43%Return on Equity (TTM)
-12.35%Revenue (TTM)
491.90MCNY73.40M · vs all stocks (USD)
Revenue per Share (TTM)
3.76CNYUpdated Sep 21, 2026Quarterly Revenue Growth
-43.90%Gross Profit (TTM)
182.32MCNY27.21M · vs all stocks (USD)
EBITDA (TTM)
-92.13MCNY-13.75M · vs all stocks (USD)
Net Income (TTM)
-270.79MCNY-40.41M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
-57.57%Operating Cash Flow (TTM)
-21.34MCNY-3.18M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-8.02MCNY-1.20M · vs all stocks (USD)
Payout Ratio
0.00%Minority Interest (Equity)
8.87MCNYFY2025 · Dec 31, 2025Revenue
541.45MCNYFY2025 · Dec 31, 2025Cost of Goods Sold
310.57MCNYFY2025 · Dec 31, 2025Gross Profit
230.88MCNYFY2025 · Dec 31, 2025Operating Income
-121.77MCNY-18.17M · vs all stocks (USD)
Pre-tax Income
-238.76MCNYFY2025 · Dec 31, 2025Income Tax Expense
-3.33MCNYFY2025 · Dec 31, 2025Net Income
-235.43MCNYFY2025 · Dec 31, 2025EBIT
-237.37MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
-2.32MCNYFY2025 · Dec 31, 2025Research & Development
88.24MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
176.65MCNYFY2025 · Dec 31, 2025Other Operating Expenses
8.10MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
6.41MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
1.39MCNYFY2025 · Dec 31, 2025EPS (Basic)
-1.77CNYFY2025 · Dec 31, 2025EPS (Diluted)
-1.77CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
130.66MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
130.66MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-235.43MCNYFY2025 · Dec 31, 2025Minority Interests (P&L)
4.16MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
-231.85MCNYFY2025 · Dec 31, 2025Free Cash Flow
-281.01MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
648.24MCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-235.43MCNYFY2025 · Dec 31, 2025Other Non-cash Items
3.88MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-8.71MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
8.41MCNYFY2025 · Dec 31, 2025Capital Expenditures
-49.17MCNYFY2025 · Dec 31, 2025Purchase of Investments
-1.27BCNYFY2025 · Dec 31, 2025Sale of Investments
1.65BCNYFY2025 · Dec 31, 2025Other Investing Activity
-971.64KCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
332.92MCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-4.96MCNYFY2025 · Dec 31, 2025Common Dividends Paid
-17.87MCNYFY2025 · Dec 31, 2025Other Financing Charges
-4.42MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
-27.26MCNYFY2025 · Dec 31, 2025Shares Outstanding
130.89MSharesUpdated Sep 21, 2026Float Shares
72.36MSharesUpdated Sep 21, 2026% Held by Insiders
45.53%vs all stocks
% Held by Institutions
2.70%vs all stocks
Total Cash (MRQ)
823.92MCNY122.95M · vs all stocks (USD)
Total Cash per Share (MRQ)
6.29CNYUpdated Sep 21, 2026Total Debt (MRQ)
30.94MCNY4.62M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.0148xCurrent Ratio (MRQ)
4.37xBook Value per Share (MRQ)
15.91CNYUpdated Sep 21, 2026Total Assets
2.58BCNY384.47M · vs all stocks (USD)
Total Current Assets
1.23BCNYFY2025 · Dec 31, 2025Total Liabilities
407.14MCNYFY2025 · Dec 31, 2025Total Non-current Assets
1.35BCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
98.30MCNYFY2025 · Dec 31, 2025Total Current Liabilities
308.85MCNYFY2025 · Dec 31, 2025Cash
648.24MCNYFY2025 · Dec 31, 2025Cash Equivalents
84.64KCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
648.33MCNYFY2025 · Dec 31, 2025Other Short-term Investments
170.63MCNYFY2025 · Dec 31, 2025Accounts Receivable
62.16MCNYFY2025 · Dec 31, 2025Inventory
82.94MCNYFY2025 · Dec 31, 2025Accounts Payable
33.13MCNYFY2025 · Dec 31, 2025Short-term Debt
67.07MCNYFY2025 · Dec 31, 2025Other Current Liabilities
2.65MCNYFY2025 · Dec 31, 2025Long-term Debt
3.90MCNYFY2025 · Dec 31, 2025Common Stock (Book)
130.89MCNYFY2025 · Dec 31, 2025Retained Earnings
138.83MCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
2.17BCNY323.72M · vs all stocks (USD)
52-Week Low
22.37CNYUpdated Sep 21, 202652-Week High
50.68CNYUpdated Sep 21, 202652-Week Change
-32.66%vs all stocks
Beta
-0.3290xvs all stocks
50-Day MA
26.56CNYUpdated Sep 21, 2026200-Day MA
30.32CNYUpdated Sep 21, 2026Avg 10-Day Volume
4.68MSharesUpdated Sep 21, 2026Avg 30-Day Volume
6.71MSharesUpdated Sep 21, 2026Diluted EPS (TTM)
-2.07CNYUpdated Sep 21, 2026Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
Low earnings qualitySignificant
Earnings Quality Score: -0.59
Altman Z-Score 5.25: safe zoneNotable
Altman Z-Score: 5.25
Supply Chain
Midstream position: 5 outgoing, 4 incoming connectionsNotable
Outgoing: 5.00Incoming: 4.00
Companies that share the same coordination system — how they create, deliver, or capture value.
Arvinas Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Regenxbio Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Shandong Sinobioway Biomedicine Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Daewoong Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Nanhua Bio-Medicine Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Onconic Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Capricor Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Chison Medical Technologies Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Tibet Aim Pharm Inc.
Tier 1ProductionApproval-Gated PipelineRule
Huaren Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow